This book examines stealth liposomes from a multidisciplinary approach, which includes theoretical polymer physics, organic synthesis, colloid science, and biology. Discussions include theory, chemistry, biochemistry, pharmacology, preclinical studies in model systems, and medical applications in humans.

Many specialists are not familiar with both drug delivery and the molecular biology of DNA vectors. Liposomes in Gene Delivery covers both-molecular biologists will gain a basic knowledge of lipids, liposomes, and other gene delivery vehicles; lipid and drug delivery scientists will better understand DNA, molecular biology, and DNA manipulation. Topics include an introduction to nucleic acids, a theoretical description of DNA, recombinant technology, lipids and liposomes, stability and interaction properties of lipids and liposomes, complexation of lipids and liposomes with DNA plasmids, gene expression of genosomes in various models, structure-activity relationships, and transfection models. This is an excellent introductory text for graduate students, scientists, and researchers in molecular and cell biology, genetics, biochemistry, physical chemistry, colloid science, pharmacology, molecular science, and medicine.

Liposomes have received increased attention in recent years. Nevertheless, liposomes, due to their various forms and applications, require further investigation. These structures can deliver both hydrophilic and hydrophobic drugs. The preparation of liposomes results in different properties for these systems. In addition, there are many factors and difficulties that affect the development of liposome drug delivery structures.The purpose of this book is to concentrate on recent developments in liposomes. The articles collected in this book are contributions by invited researchers with long-standing experience in different research areas. We hope that the material presented here is understandable to a broad audience, not only scientists but also people with a general background in many different biological sciences. This volume offers up-to-date, expert reviews of the fast-moving field of liposomes and is divided in two major sections: 1. Introduction; 2. Liposomes general properties

First Published in 2017. Routledge is an imprint of Taylor & Francis, an Informa company.

Liposome Technology, Second Edition, is an updated, expanded new edition of a classic volume in the field. It covers all aspects of liposome technology, including liposome preparation and analysis, drug entrapment, and techniques used for in vivo and in vitro evaluation of liposomes. Leading authorities have contributed 70 chapters to create what is destined to be the standard liposome technology book for the 1990s. Many of the chapters describe methodologies practiced in authors' laboratories and provide specific examples of how these methodologies are applied in specific circumstances. Liposome Technology, Second Edition will be an essential reference volume for academic and industrial researchers in pharmacology, pharmacy, medicine, biochemistry, and immunology. What's new in the 2nd Edition? The 2nd Edition covers significant developments in liposome technology that have occurred since the publication of the 1st Edition in 1982. These developments include the following: New preparative procedures Special approaches to accommodate the incorporation of certain drugs New targeting techniques Large scale production of liposomes, patents, and clinical trials

Critically reviews the applications of liposomes, including theoretical physics; chemistry; energy conversion; ecology; genetic engineering; food industry; cosmetics; and medicine, as well as their characteristics and properties. It also presents recent developments, such as Stealth liposomes.

This book provides an up-to-date evaluation of clinical aspects of newly available "long-circulating liposome" formulations. Based on results from numerous clinical studies, the book describes the fundamentals of this new technology, discusses how it may influence the pharmacology of existing well-known agents reformulated in this manner, and elaborates on future expectations. It provides the practicing clinician - in particular, oncologists and critical care infectious disease physicians - with the tools needed to use these new formulations towards the best outcome for the patient.